Xspray Pharma: XS003 NDA on the horizon
14 juli, 07:55
14 juli, 07:55
Redeye raises its base case following Xspray’s announcement that XS003 has achieved bioequivalence with Tasigna, paving the way for an NDA submission in the near term. Meanwhile, the company’s lead candidate, Dasynoc, has a PDUFA date in October, offering another near-term catalyst.
14 juli, 07:55
Redeye raises its base case following Xspray’s announcement that XS003 has achieved bioequivalence with Tasigna, paving the way for an NDA submission in the near term. Meanwhile, the company’s lead candidate, Dasynoc, has a PDUFA date in October, offering another near-term catalyst.
Inflationen
Aktieanalyser
Rapporter
Inflationen
Aktieanalyser
Rapporter
1 DAG %
Senast
Idag, 17:14
Tjeckien köper 44 Leopard-stridsvagnar
OMX Stockholm 30
1 DAG %
Senast
2 609,15